Newsletter

Stay up to date on all things colon cancer. Sign up and we’ll send you the latest news, resources, scientific breakthroughs, events, tips, and much more.

Exercise And Colon Cancer Treatment

November 21, 2019

Overview

This study is looking at how exercise may prevent the recurrence of colon cancer in patients who have completed their treatment. The primary objective is to determine if aerobic exercise can reduce systemic inflammation.  The secondary objectives are to determine if exercise can reduce: 1) insulin resistance 2) circulating tumor cells. Another, exploratory objective is to determine if exercise can improve mitochondrial respiration rates and fatty acid oxidation.

 

Study Information

This trial will involve an estimated 60 subjects who have completed standard treatment for colon cancer. Some of the participants will partake in 12-weeks of moderate-intensity aerobic exercise, and the others will maintain their pre-study levels of physical activity. The study began on August 16th 2019 and is estimated to be completed on July 21st 2022.

 

Inclusion Criteria

 

  • Over 18 years old
  • Confirmed stage III colon cancer
  • Completed surgical resection within 1-24 months
  • Completed chemotherapy (if applicable) within 1-24 months
  • Self-report, on average over the past one-month, less than or 90 minutes per week of moderate-intensity or vigorous-intensity physical activity
  • Provide written approval by physician or other qualified healthcare provider
  • No planned major surgery during the study period (including colostomy reversal; chemotherapy infusion port removal is permitted)
  • Readiness to exercise [as determined by a modified version the Physical
  • Activity Readiness Questionnaire (PAR-Q)
  • Allow the collection and storage of specimens and data for future use 1.10
  • Willing to be randomized

 

Exclusion Criteria

 

  • Evidence of metastatic colon cancer
  • Concurrently actively treated other cancer (except non-melanoma skin cancer or in situ cancers)
  • Currently enrolled in another clinical trial of weight loss, physical activity, or dietary intervention
  • Current body mass greater than or equal to 181 kg
  • Unable to provide a baseline fasting blood sample
  • Unable or unwilling to give informed consent
  • Unable or unwilling to be randomized
  • Or any other condition that may impede testing of the study hypothesis or make it unsafe to engage in the exercise program (as determined by the investigative team)

 

Location

You may participate in this study at Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States, 70808. For further information, please contact Kaylee T. Woodard at kaylee.woodard@pbrc.edu.

 

Sponsors/Collaborators

This study is sponsored by Pennington Biomedical Research Center and the National Cancer Institute (NCI). The Principal Investigator is Justin C Brown, Ph.D. of the Pennington Biomedical Center.

Clinical Trials

View All Clinical Trials

DC Vaccine in Colorectal Cancer

This study is assessing the safety, tolerability and immune response rate the of mDC3 vaccine in patients with colorectal cancer.

Diet Modulation of Bacterial Sulfur and Bile Acid Metabolism and Colon Cancer Risk

This diet-intervention trial focuses on African American subjects who are at higher risk for developing colorectal cancer (CRC). Two diets, one…

Green Tea and Milk Thistle to Colorectal Cancer Patients

Colorectal cancer is the third most common form of cancer found in the United States, and surgical resection (removal) provides the best chance for…

Participatory Research to Advance Colon Cancer Prevention

The goal of this study is to test strategies to raise rates of colorectal cancer screening among the Latino population. This study will be split…

Reducing Rural Colon Cancer Disparities

This study is exploring the difference in outcomes for cancer patients in rural vs. urban areas. Southern Illinois will be used as the prime…

Young-Onset Microsatellite-Stable Colorectal Cancer

The goal of this laboratory research study is to learn more about genetic factors that may influence the risk for developing colorectal cancer at a…

PalloV-CC in Colon Cancer

This study is looking at the effects of the PalloV CC vaccination on patients with colon cancer. The primary goals are to understand the safety of…

Niclosamide in Patients With Resectable Colon Cancer

This study is examining the safety of the drug Niclosamide in patients with colon cancer that are undergoing primary resection (cutting out) of…

Make a comment and share this article on your profile.

Write a comment for your publication

Successfully Shared!

View on my Profile

Send this to a friend